In vitro and in silico PTP-1B inhibition and in vivo antidiabetic activity of semisynthetic moronic acid derivatives
[Display omitted] Six derivatives (1–6) of moronic acid were semi-synthesized and their in vitro protein tyrosine phosphatase 1B (PTP-1B) inhibition activity assessed. Derivatives 2 (IC50=10.8±0.5μM) and 6 (IC50=7.5±0.1μM) displayed the most potent inhibitory activity. Therefore, they (50mg/Kg) were...
Saved in:
Published in: | Bioorganic & medicinal chemistry letters Vol. 26; no. 8; pp. 2018 - 2022 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
Elsevier Ltd
15-04-2016
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | [Display omitted]
Six derivatives (1–6) of moronic acid were semi-synthesized and their in vitro protein tyrosine phosphatase 1B (PTP-1B) inhibition activity assessed. Derivatives 2 (IC50=10.8±0.5μM) and 6 (IC50=7.5±0.1μM) displayed the most potent inhibitory activity. Therefore, they (50mg/Kg) were tested for their antidiabetic effect in vivo using a non-insulin dependent diabetes mellitus rat model. The results indicated that they decrease plasma glucose levels during all the experiment (p <0.05). Docking analysis of 2 and 6 with PTP-1B orthosteric site A and allosteric site B, showed that 2 had polar and Van der Waals interactions in both sites with Val49, Gln262, Met258, Phe182, Ala217, Ile219 and Gly259, displaying more affinity for site A. Compound 6 showed polar interaction with Gln262 and Van der Waals with Val49, Ile219, Gly259, Arg254, Ala27, Phe52, Met258, Asp48 and Phe182, suggesting that the potential binding site is localized in site B, close to the catalytic site A. Therefore, derivatives 2 and 6 have potential for the development of antidiabetic agents. |
---|---|
AbstractList | Six derivatives (1-6) of moronic acid were semi-synthesized and their in vitro protein tyrosine phosphatase 1B (PTP-1B) inhibition activity assessed. Derivatives 2 (IC sub(50) = 10.8 plus or minus 0.5 mu M) and 6 (IC sub(50) = 7.5 plus or minus 0.1 mu M) displayed the most potent inhibitory activity. Therefore, they (50 mg/Kg) were tested for their antidiabetic effect in vivo using a non-insulin dependent diabetes mellitus rat model. The results indicated that they decrease plasma glucose levels during all the experiment (p <0.05). Docking analysis of 2 and 6 with PTP-1B orthosteric site A and allosteric site B, showed that 2 had polar and Van der Waals interactions in both sites with Val49, Gln262, Met258, Phe182, Ala217, Ile219 and Gly259, displaying more affinity for site A. Compound 6 showed polar interaction with Gln262 and Van der Waals with Val49, Ile219, Gly259, Arg254, Ala27, Phe52, Met258, Asp48 and Phe182, suggesting that the potential binding site is localized in site B, close to the catalytic site A. Therefore, derivatives 2 and 6 have potential for the development of antidiabetic agents. Six derivatives (1-6) of moronic acid were semi-synthesized and their in vitro protein tyrosine phosphatase 1B (PTP-1B) inhibition activity assessed. Derivatives 2 (IC50=10.8 ± 0.5 μM) and 6 (IC50=7.5 ± 0.1 μM) displayed the most potent inhibitory activity. Therefore, they (50mg/Kg) were tested for their antidiabetic effect in vivo using a non-insulin dependent diabetes mellitus rat model. The results indicated that they decrease plasma glucose levels during all the experiment (p <0.05). Docking analysis of 2 and 6 with PTP-1B orthosteric site A and allosteric site B, showed that 2 had polar and Van der Waals interactions in both sites with Val49, Gln262, Met258, Phe182, Ala217, Ile219 and Gly259, displaying more affinity for site A. Compound 6 showed polar interaction with Gln262 and Van der Waals with Val49, Ile219, Gly259, Arg254, Ala27, Phe52, Met258, Asp48 and Phe182, suggesting that the potential binding site is localized in site B, close to the catalytic site A. Therefore, derivatives 2 and 6 have potential for the development of antidiabetic agents. [Display omitted] Six derivatives (1–6) of moronic acid were semi-synthesized and their in vitro protein tyrosine phosphatase 1B (PTP-1B) inhibition activity assessed. Derivatives 2 (IC50=10.8±0.5μM) and 6 (IC50=7.5±0.1μM) displayed the most potent inhibitory activity. Therefore, they (50mg/Kg) were tested for their antidiabetic effect in vivo using a non-insulin dependent diabetes mellitus rat model. The results indicated that they decrease plasma glucose levels during all the experiment (p <0.05). Docking analysis of 2 and 6 with PTP-1B orthosteric site A and allosteric site B, showed that 2 had polar and Van der Waals interactions in both sites with Val49, Gln262, Met258, Phe182, Ala217, Ile219 and Gly259, displaying more affinity for site A. Compound 6 showed polar interaction with Gln262 and Van der Waals with Val49, Ile219, Gly259, Arg254, Ala27, Phe52, Met258, Asp48 and Phe182, suggesting that the potential binding site is localized in site B, close to the catalytic site A. Therefore, derivatives 2 and 6 have potential for the development of antidiabetic agents. Six derivatives (1-6) of moronic acid were semi-synthesized and their in vitro protein tyrosine phosphatase 1B (PTP-1B) inhibition activity assessed. Derivatives 2 (IC50=10.8 ± 0.5 μM) and 6 (IC50=7.5 ± 0.1 μM) displayed the most potent inhibitory activity. Therefore, they (50mg/Kg) were tested for their antidiabetic effect in vivo using a non-insulin dependent diabetes mellitus rat model. The results indicated that they decrease plasma glucose levels during all the experiment (p <0.05). Docking analysis of 2 and 6 with PTP-1B orthosteric site A and allosteric site B, showed that 2 had polar and Van der Waals interactions in both sites with Val49, Gln262, Met258, Phe182, Ala217, Ile219 and Gly259, displaying more affinity for site A. Compound 6 showed polar interaction with Gln262 and Van der Waals with Val49, Ile219, Gly259, Arg254, Ala27, Phe52, Met258, Asp48 and Phe182, suggesting that the potential binding site is localized in site B, close to the catalytic site A. Therefore, derivatives 2 and 6 have potential for the development of antidiabetic agents. |
Author | Paoli, Paolo Estrada-Soto, Samuel Ramírez-Espinosa, Juan J. Navarrete-Vázquez, Gabriel Hidalgo-Figueroa, Sergio Cerón-Romero, Litzia Camici, Guido Flores-Morales, Virginia Rios, María Yolanda |
Author_xml | – sequence: 1 givenname: Litzia surname: Cerón-Romero fullname: Cerón-Romero, Litzia organization: Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico – sequence: 2 givenname: Paolo orcidid: 0000-0001-6448-7266 surname: Paoli fullname: Paoli, Paolo organization: Dipartimento di Scienze Biomediche Sperimentali e Cliniche ‘Mario Serio’, Sezione di Scienze Biochimiche, Universitá degli Studi di Firenze, Viale Morgagni 50, 50134 Firenze, Italy – sequence: 3 givenname: Guido orcidid: 0000-0001-8606-9348 surname: Camici fullname: Camici, Guido organization: Dipartimento di Scienze Biomediche Sperimentali e Cliniche ‘Mario Serio’, Sezione di Scienze Biochimiche, Universitá degli Studi di Firenze, Viale Morgagni 50, 50134 Firenze, Italy – sequence: 4 givenname: Virginia surname: Flores-Morales fullname: Flores-Morales, Virginia organization: Unidad Académica de Ciencias Químicas (LSAyB), Universidad Autónoma de Zacatecas Campus Siglo XXI, Carretera Zacatecas-Guadalajara, Km. 6.0, Ejido la Escondida, 98160 Zacatecas, Zacatecas, Mexico – sequence: 5 givenname: María Yolanda surname: Rios fullname: Rios, María Yolanda organization: Centro de Investigaciones Químicas, IICBA, Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico – sequence: 6 givenname: Juan J. surname: Ramírez-Espinosa fullname: Ramírez-Espinosa, Juan J. organization: Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico – sequence: 7 givenname: Sergio surname: Hidalgo-Figueroa fullname: Hidalgo-Figueroa, Sergio organization: Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico – sequence: 8 givenname: Gabriel surname: Navarrete-Vázquez fullname: Navarrete-Vázquez, Gabriel organization: Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico – sequence: 9 givenname: Samuel orcidid: 0000-0002-5850-1321 surname: Estrada-Soto fullname: Estrada-Soto, Samuel email: enoch@uaem.mx organization: Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Col. Chamilpa, 62209 Cuernavaca, Morelos, Mexico |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26961283$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkcFq3DAQhkVJSTZpXqCHomMvdke2LEvQSxuaNBBoDin0JixZJrPYUippDfv21WaTHtvTiJlvfsR85-TEB-8Iec-gZsDEp21tFjvXTXnX0NQgmzdkw7jgVcuhOyEbUAIqqfivM3Ke0haAceD8lJw1QgnWyHZD8q2nK-YY6OBHip4mnNEGev9wX7GvpfGIBjMG_zpfcT2wGUccjMto6WAzlog9DRNNbsG09_nxebKEGPwzgSMdXcR1KKhL78jbaZiTu3ypF-Tn9beHq-_V3Y-b26svd5VtpcqVYIJZMNPUD0JayZkRDFojJTfc8q5rmbRiVLLrOwDRtJYZPvXWcjU1QwvQXpCPx9ynGH7vXMq6_M66eR68C7ukWa9Adbwrl_g_2gtQBRUFbY6ojSGl6Cb9FHEZ4l4z0AcxeqsPYvRBjIZGFzFl6cNL_s4sbvy78mqiAJ-PgCsHWdFFnSw6b92I0dmsx4D_yv8DPDqgVQ |
CitedBy_id | crossref_primary_10_1139_cjpp_2021_0526 crossref_primary_10_1007_s12272_017_0992_0 crossref_primary_10_1016_j_molstruc_2018_01_011 crossref_primary_10_1016_j_heliyon_2024_e34000 crossref_primary_10_1002_ddr_21422 crossref_primary_10_1002_bmc_4381 crossref_primary_10_3390_molecules28052333 crossref_primary_10_1007_s00044_023_03014_0 crossref_primary_10_1007_s11306_023_02008_8 crossref_primary_10_1111_jphp_12933 crossref_primary_10_1016_j_biopha_2018_09_074 crossref_primary_10_1016_j_bmc_2020_115817 crossref_primary_10_3390_ijms22179508 crossref_primary_10_1007_s42250_022_00415_3 crossref_primary_10_1016_j_bmc_2016_04_007 crossref_primary_10_1016_j_bioorg_2022_105626 crossref_primary_10_1039_D3SM01035J crossref_primary_10_1016_j_indcrop_2017_11_025 crossref_primary_10_1016_j_bioorg_2016_12_004 crossref_primary_10_2174_1573399815666190510112035 |
Cites_doi | 10.1016/j.ejmech.2014.09.036 10.1111/j.1463-1326.2008.00869.x 10.1074/jbc.M112.441469 10.1111/cbdd.12102 10.1038/nrd895 10.1073/pnas.94.25.13420 10.1016/S0065-7743(05)40011-1 10.1016/j.ejmech.2011.03.005 10.1016/j.fitote.2012.05.014 10.1016/j.ejmech.2010.02.049 10.1016/j.phymed.2013.01.013 10.1016/j.drudis.2007.03.011 10.1002/anie.200461517 |
ContentType | Journal Article |
Copyright | 2016 Elsevier Ltd Copyright © 2016 Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: 2016 Elsevier Ltd – notice: Copyright © 2016 Elsevier Ltd. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7QO 8FD FR3 P64 |
DOI | 10.1016/j.bmcl.2016.02.082 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | Engineering Research Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology Chemistry |
EISSN | 1464-3405 |
EndPage | 2022 |
ExternalDocumentID | 10_1016_j_bmcl_2016_02_082 26961283 S0960894X16302074 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 4.4 457 4G. 5GY 5VS 7-5 71M 8P~ 9JM 9JN AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARLI AATCM AAXUO ABBQC ABFNM ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABYKQ ABZDS ACDAQ ACGFS ACIUM ACRLP ADBBV ADECG ADEZE ADUVX AEBSH AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AFZHZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJSZI ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV CS3 D0L DOVZS EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FLBIZ FNPLU FYGXN G-Q GBLVA IHE J1W KOM LCYCR LZ2 M29 M2Z M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SCC SDF SDG SDP SES SPC SPCBC SSH SSK SSP SSU SSZ T5K YK3 ZMT ~02 ~G- AAXKI AKRWK CGR CUY CVF ECM EIF NPM .HR 53G 6TJ AAQXK AAYXX ABTAH ABXDB ACNNM ADMUD AFFNX AFJKZ AGRDE ASPBG AVWKF AZFZN CITATION FEDTE FGOYB G-2 HEA HMK HMO HMS HMT HVGLF HZ~ R2- SAE SCB SEW SOC SPT WUQ XPP Y6R ZY4 7X8 7QO 8FD FR3 P64 |
ID | FETCH-LOGICAL-c389t-6161c0bff7a68c841b6103b884b4c455318c6d9857500623c1b4f7cc49f2a3003 |
ISSN | 0960-894X |
IngestDate | Fri Oct 25 05:05:52 EDT 2024 Fri Oct 25 07:57:27 EDT 2024 Thu Sep 26 16:02:21 EDT 2024 Sat Sep 28 08:05:26 EDT 2024 Fri Feb 23 02:26:13 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Moronic acid derivatives Enzyme inhibition PTP-1B RGKMKULXFZOUPF-BQSMYOSZSA-N SXYLITRDEAEYTJ-MGPMMZCJSA-N Diabetes Molecular docking |
Language | English |
License | Copyright © 2016 Elsevier Ltd. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c389t-6161c0bff7a68c841b6103b884b4c455318c6d9857500623c1b4f7cc49f2a3003 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-5850-1321 0000-0001-6448-7266 0000-0001-8606-9348 |
PMID | 26961283 |
PQID | 1776094526 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_1790954528 proquest_miscellaneous_1776094526 crossref_primary_10_1016_j_bmcl_2016_02_082 pubmed_primary_26961283 elsevier_sciencedirect_doi_10_1016_j_bmcl_2016_02_082 |
PublicationCentury | 2000 |
PublicationDate | 2016-04-15 |
PublicationDateYYYYMMDD | 2016-04-15 |
PublicationDate_xml | – month: 04 year: 2016 text: 2016-04-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Bioorganic & medicinal chemistry letters |
PublicationTitleAlternate | Bioorg Med Chem Lett |
PublicationYear | 2016 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Zhang, Zhang (b0055) 2007; 12 Ngoc, Le Thy (b0070) 2012; 3 Johnson, Ermolieff, Jirousek (b0065) 2002; 1 ADA Diabetes care volume 37, supplement 1, January 2014 [on line October 28th 2014 Rios, López-Martínez, López-Vallejo, Medina-Franco, Villalobos-Molina, Ibarra-Barajas, Navarrete-Vazquez, Hidalgo-Figueroa, Hernández-Abreu, Estrada-Soto (b0045) 2012; 83 Bialy, Waldmann (b0080) 2005; 44 Hidalgo-Figueroa, Ramírez-Espinosa, Estrada-Soto, Almanza-Pérez, Román-Ramos, Alarcón-Aguilar, Hernández-Rosado, Moreno-Díaz, Díaz-Coutiño, Navarrete-Vázquez (b0005) 2013; 81 Ramírez-Espinosa, Rios, López-Martínez, López-Vallejo, Medina-Franco, Paoli, Camici, Navarrete-Vázquez, Ortiz-Andrade, Estrada-Soto (b0035) 2011; 46 Ortiz-Andrade, Sánchez-Salgado, Navarrete-Vázquez, Webster, Binnie, García-Jiménez, León-Rivera, Cigarroa-Vázquez, Villalobos-Molina, Estrada-Soto (b0090) 2008; 10 . Ramírez-Espinosa, García-Jiménez, Ríos, Medina-Franco, López-Vallejo, Webster, Binnie, Ibarra-Barajas, Ortiz-Andrade, Estrada-Soto (b0050) 2013; 20 Puius, Zhao, Sullivan, Lawrence, Almo, Zhang (b0085) 1997; 94 Ramírez-Espinosa, Rios, Paoli, Flores-Morales, Camici, de la Rosa-Lugo, Hidalgo-Figueroa, Navarrete-Vázquez, Estrada-Soto (b0040) 2014; 87 Sarabu, Tilley (b0025) 2005; 40 WHO Fact sheet #312 January 2015 [on line September 28th 2014 IDF Atlas Sixth edition 2013 [on line September 22th 2014 b0075 Torres-Piedra, Ortiz-Andrade, Villalobos-Molina, Singh, Medina-Franco, Webster, Binnie, Navarrete-Vázquez, Estrada-Soto (b0030) 2010; 45 Bettaieb, Bakke, Nagata, Matsuo, Xi, Liu, AbouBechara, Melhem, Stanhope, Cummings, Graham, Bremer, Zhang, Lyssiotis, Zhang, Cantley, Havel, Haj (b0060) 2013; 288 Ramírez-Espinosa (10.1016/j.bmcl.2016.02.082_b0040) 2014; 87 Johnson (10.1016/j.bmcl.2016.02.082_b0065) 2002; 1 Bialy (10.1016/j.bmcl.2016.02.082_b0080) 2005; 44 10.1016/j.bmcl.2016.02.082_b0010 10.1016/j.bmcl.2016.02.082_b0020 Sarabu (10.1016/j.bmcl.2016.02.082_b0025) 2005; 40 10.1016/j.bmcl.2016.02.082_b0015 Zhang (10.1016/j.bmcl.2016.02.082_b0055) 2007; 12 Rios (10.1016/j.bmcl.2016.02.082_b0045) 2012; 83 Hidalgo-Figueroa (10.1016/j.bmcl.2016.02.082_b0005) 2013; 81 Ngoc (10.1016/j.bmcl.2016.02.082_b0070) 2012; 3 Bettaieb (10.1016/j.bmcl.2016.02.082_b0060) 2013; 288 Ramírez-Espinosa (10.1016/j.bmcl.2016.02.082_b0035) 2011; 46 Ortiz-Andrade (10.1016/j.bmcl.2016.02.082_b0090) 2008; 10 Ramírez-Espinosa (10.1016/j.bmcl.2016.02.082_b0050) 2013; 20 Puius (10.1016/j.bmcl.2016.02.082_b0085) 1997; 94 Torres-Piedra (10.1016/j.bmcl.2016.02.082_b0030) 2010; 45 |
References_xml | – volume: 94 start-page: 13420 year: 1997 ident: b0085 publication-title: Proc. Natl. Acad. Sci. U.S.A. contributor: fullname: Zhang – volume: 1 start-page: 696 year: 2002 ident: b0065 publication-title: Nat. Rev. Drug Disc. contributor: fullname: Jirousek – ident: b0075 – volume: 40 start-page: 167 year: 2005 ident: b0025 publication-title: Annu. Rep. Med. Chem. contributor: fullname: Tilley – volume: 83 start-page: 1023 year: 2012 ident: b0045 publication-title: Fitoterapia contributor: fullname: Estrada-Soto – volume: 81 start-page: 474 year: 2013 ident: b0005 publication-title: Chem. Biol. Drug. Des. contributor: fullname: Navarrete-Vázquez – volume: 3 start-page: 1 year: 2012 ident: b0070 publication-title: Adv. Nat. Sci.: Nanosci. Nanotechnol. contributor: fullname: Le Thy – volume: 87 start-page: 316 year: 2014 ident: b0040 publication-title: Eur. J. Med. Chem. contributor: fullname: Estrada-Soto – volume: 20 start-page: 571 year: 2013 ident: b0050 publication-title: Phytomedicine contributor: fullname: Estrada-Soto – volume: 46 start-page: 2243 year: 2011 ident: b0035 publication-title: Eur. J. Med. Chem. contributor: fullname: Estrada-Soto – volume: 45 start-page: 2606 year: 2010 ident: b0030 publication-title: Eur. J. Med. Chem. contributor: fullname: Estrada-Soto – volume: 44 start-page: 3814 year: 2005 ident: b0080 publication-title: Angew. Chem., Int. Ed. contributor: fullname: Waldmann – volume: 10 start-page: 1097 year: 2008 ident: b0090 publication-title: Diabetes Obes. Metab. contributor: fullname: Estrada-Soto – volume: 12 start-page: 373 year: 2007 ident: b0055 publication-title: Drug Discovery Today contributor: fullname: Zhang – volume: 288 start-page: 17360 year: 2013 ident: b0060 publication-title: J. Biol. Chem. contributor: fullname: Haj – volume: 87 start-page: 316 year: 2014 ident: 10.1016/j.bmcl.2016.02.082_b0040 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2014.09.036 contributor: fullname: Ramírez-Espinosa – volume: 10 start-page: 1097 year: 2008 ident: 10.1016/j.bmcl.2016.02.082_b0090 publication-title: Diabetes Obes. Metab. doi: 10.1111/j.1463-1326.2008.00869.x contributor: fullname: Ortiz-Andrade – ident: 10.1016/j.bmcl.2016.02.082_b0020 – volume: 288 start-page: 17360 year: 2013 ident: 10.1016/j.bmcl.2016.02.082_b0060 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M112.441469 contributor: fullname: Bettaieb – volume: 81 start-page: 474 year: 2013 ident: 10.1016/j.bmcl.2016.02.082_b0005 publication-title: Chem. Biol. Drug. Des. doi: 10.1111/cbdd.12102 contributor: fullname: Hidalgo-Figueroa – volume: 1 start-page: 696 year: 2002 ident: 10.1016/j.bmcl.2016.02.082_b0065 publication-title: Nat. Rev. Drug Disc. doi: 10.1038/nrd895 contributor: fullname: Johnson – volume: 94 start-page: 13420 year: 1997 ident: 10.1016/j.bmcl.2016.02.082_b0085 publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.94.25.13420 contributor: fullname: Puius – volume: 40 start-page: 167 year: 2005 ident: 10.1016/j.bmcl.2016.02.082_b0025 publication-title: Annu. Rep. Med. Chem. doi: 10.1016/S0065-7743(05)40011-1 contributor: fullname: Sarabu – volume: 3 start-page: 1 year: 2012 ident: 10.1016/j.bmcl.2016.02.082_b0070 publication-title: Adv. Nat. Sci.: Nanosci. Nanotechnol. contributor: fullname: Ngoc – volume: 46 start-page: 2243 year: 2011 ident: 10.1016/j.bmcl.2016.02.082_b0035 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2011.03.005 contributor: fullname: Ramírez-Espinosa – ident: 10.1016/j.bmcl.2016.02.082_b0010 – volume: 83 start-page: 1023 year: 2012 ident: 10.1016/j.bmcl.2016.02.082_b0045 publication-title: Fitoterapia doi: 10.1016/j.fitote.2012.05.014 contributor: fullname: Rios – volume: 45 start-page: 2606 year: 2010 ident: 10.1016/j.bmcl.2016.02.082_b0030 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2010.02.049 contributor: fullname: Torres-Piedra – volume: 20 start-page: 571 year: 2013 ident: 10.1016/j.bmcl.2016.02.082_b0050 publication-title: Phytomedicine doi: 10.1016/j.phymed.2013.01.013 contributor: fullname: Ramírez-Espinosa – volume: 12 start-page: 373 year: 2007 ident: 10.1016/j.bmcl.2016.02.082_b0055 publication-title: Drug Discovery Today doi: 10.1016/j.drudis.2007.03.011 contributor: fullname: Zhang – ident: 10.1016/j.bmcl.2016.02.082_b0015 – volume: 44 start-page: 3814 year: 2005 ident: 10.1016/j.bmcl.2016.02.082_b0080 publication-title: Angew. Chem., Int. Ed. doi: 10.1002/anie.200461517 contributor: fullname: Bialy |
SSID | ssj0014044 |
Score | 2.333364 |
Snippet | [Display omitted]
Six derivatives (1–6) of moronic acid were semi-synthesized and their in vitro protein tyrosine phosphatase 1B (PTP-1B) inhibition activity... Six derivatives (1-6) of moronic acid were semi-synthesized and their in vitro protein tyrosine phosphatase 1B (PTP-1B) inhibition activity assessed.... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 2018 |
SubjectTerms | Animals Blood Glucose - drug effects Computer Simulation Diabetes Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - enzymology Dose-Response Relationship, Drug Enzyme inhibition Hypoglycemic Agents - chemical synthesis Hypoglycemic Agents - chemistry Hypoglycemic Agents - pharmacology Molecular docking Molecular Docking Simulation Molecular Structure Moronic acid derivatives Oleanolic Acid - analogs & derivatives Oleanolic Acid - chemical synthesis Oleanolic Acid - chemistry Oleanolic Acid - pharmacology Protein Tyrosine Phosphatase, Non-Receptor Type 1 - antagonists & inhibitors Protein Tyrosine Phosphatase, Non-Receptor Type 1 - metabolism PTP-1B Rats Structure-Activity Relationship |
Title | In vitro and in silico PTP-1B inhibition and in vivo antidiabetic activity of semisynthetic moronic acid derivatives |
URI | https://dx.doi.org/10.1016/j.bmcl.2016.02.082 https://www.ncbi.nlm.nih.gov/pubmed/26961283 https://search.proquest.com/docview/1776094526 https://search.proquest.com/docview/1790954528 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6TQJeEHRcyk1GQrxEmXJxEudxK0UrYqhiBe0tih0HPK0xatJK49dzHDtpN7QJkHiJUuc0dXK-Hh-fK0JvBCwjIhCeW0Rh5BKaR24acM_1mRcLUmqlVpsGjk-TT2f03YRMBoOu7u1m7L9yGsaA1zpz9i-43d8UBuAceA5H4Doc_4jv08pZy2apbFklp5YXwGxnNp-5_hEMfJdMNl0MstTEa03bSGOF1eVbue0oAXpkrdvBXVagJeorC2Ua5uRcFk4BT7Nuy4bXVzzDUplOUbxFlfXd6yokXWs556JNIeqV-bFx1x-FlftZLYRJvPkom5-yXzJmuTJp3PpEbflN4N6tZX8lC7WBolqK2j3RtQeMEPwql99kZW9nTRx-rL01JsnT2N263JtNoFNrwIw9l6YmvvNAGPFNYuKGxIu25bvJyLc4ptvC2rOiX9iPJkP6t0XF2DfOD9iCa2eVH7dVXk3PpGvFuk_1rPSkQM0FRTwhO2gvABEIEnjvcDo5-9B7uIjXNhrun8ImdJnYw-u_dJPSdNOmqFWO5g_QfburwYcGjg_RQFRDtH9Y5Y1aXOK3uI0zbh04Q3R33AFhiO6c2NCOfdRMK9wCFwMwsaywAS42wMUb4HbXNXDxNnBxB1ysSnwFuNgCF2vg4i3gPkJf3k_m42PXtgRxOWjWjRvDBoV7rCyTPKacEp-B-h8ySgkjnESwoFAeF6luO6uzg0PuM1ImnJO0DPIQVrDHaLdSlXiKMKNJEqYCqEhOmCZMWBnGNAwJYXmYjpDTvfPsh6n8knUhkeeZ5lCmOZR5QQYcGqGoY0tmdVejk2aAolu_97rjYQbvRXvr8kqoVZ35SRJ7KYmC-DaaFLZIQENH6IkBQD_XIE5h90LDZ_84s-fo3ua_-ALtNsuVeIl26mL1ymL5F-4G3Hk |
link.rule.ids | 315,782,786,27933,27934 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+vitro+and+in+silico+PTP-1B+inhibition+and+in+vivo+antidiabetic+activity+of+semisynthetic+moronic+acid+derivatives&rft.jtitle=Bioorganic+%26+medicinal+chemistry+letters&rft.au=Cer%C3%B3n-Romero%2C+Litzia&rft.au=Paoli%2C+Paolo&rft.au=Camici%2C+Guido&rft.au=Flores-Morales%2C+Virginia&rft.date=2016-04-15&rft.pub=Elsevier+Ltd&rft.issn=0960-894X&rft.eissn=1464-3405&rft.volume=26&rft.issue=8&rft.spage=2018&rft.epage=2022&rft_id=info:doi/10.1016%2Fj.bmcl.2016.02.082&rft.externalDocID=S0960894X16302074 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0960-894X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0960-894X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0960-894X&client=summon |